Javascript must be enabled to continue!
Designing AAV Capsid Protein with viability-guided Diffusion Model
View through CrossRef
Adeno-associated virus (AAV) capsids have shown great promise as delivery vectors for gene therapy. However, the natural properties of AAV capsids impose significant limitations on their efficacy. While capsid library screening and directed evolution have facilitated the development of improved vectors, current methods for generating AAV libraries frequently yield nonviable variants that fail to assemble or package DNA. Here, we propose a viability-guided diffusion model AAVDiffusion for de novo viable AAV capsid design. AAVDiffusion iteratively denoises Gaussian vectors into vectors of AAV capsid protein sequences, yielding intermediate latent variables. By leveraging the continuous nature of these latent variables, AAVDiffusion integrates an additional viability classifier that applies gradient updates to enhance the generation of viable AAV sequences. Through extensive computational tests, AAVDiffusion exhibits superior performance in generating viable AAV sequences. Furthermore, 196 AAV candidates were identified through a selection workflow, with the potential to cross the blood-brain barrier, thereby offering safer and more effective gene therapies for brain diseases. AAVDiffusion offers a powerful and efficient computational method for designing viable AAV capsids, advancing the development of AAV vectors for gene therapy.
Title: Designing AAV Capsid Protein with viability-guided Diffusion Model
Description:
Adeno-associated virus (AAV) capsids have shown great promise as delivery vectors for gene therapy.
However, the natural properties of AAV capsids impose significant limitations on their efficacy.
While capsid library screening and directed evolution have facilitated the development of improved vectors, current methods for generating AAV libraries frequently yield nonviable variants that fail to assemble or package DNA.
Here, we propose a viability-guided diffusion model AAVDiffusion for de novo viable AAV capsid design.
AAVDiffusion iteratively denoises Gaussian vectors into vectors of AAV capsid protein sequences, yielding intermediate latent variables.
By leveraging the continuous nature of these latent variables, AAVDiffusion integrates an additional viability classifier that applies gradient updates to enhance the generation of viable AAV sequences.
Through extensive computational tests, AAVDiffusion exhibits superior performance in generating viable AAV sequences.
Furthermore, 196 AAV candidates were identified through a selection workflow, with the potential to cross the blood-brain barrier, thereby offering safer and more effective gene therapies for brain diseases.
AAVDiffusion offers a powerful and efficient computational method for designing viable AAV capsids, advancing the development of AAV vectors for gene therapy.
Related Results
The plasma proteome reveals distinct signaling pathways associated with PR3-ANCA positive and MPO-ANCA positive vasculitis
The plasma proteome reveals distinct signaling pathways associated with PR3-ANCA positive and MPO-ANCA positive vasculitis
ObjectiveDespite recent advances, the pathophysiological mechanisms underlying anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) remain incompletely underst...
Post‐translational modifications in capsid proteins of recombinant adeno‐associated virus (
AAV
) 1‐rh10 serotypes
Post‐translational modifications in capsid proteins of recombinant adeno‐associated virus (
AAV
) 1‐rh10 serotypes
Post‐translational modifications in viral capsids are known to fine‐tune and regulate several aspects of the infective life cycle of several viruses in the host. Recombinant viruse...
Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
Abstract
Recombinant Adeno-associated viruses (rAAVs) are one of the most commonly used vectors for a variety of gene therapy applications. In th...
The Use of Adeno-associated virus (AAV) in Vaccine Development
The Use of Adeno-associated virus (AAV) in Vaccine Development
Adeno-associated virus (AAV) is a very tiny (20-26 nm) icosahedral and non-enveloped virus, and it belongs to the Parvoviridae family. AAV vectors are the most widely used ...
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
The seventh in the series of ETP Symposia (see
Rapid Communications in Mass Spectrometry
2012,
26
, ...
Changing incidence and serotype trends in ANCA-associated vasculitis: a 30-year population-based study in Norfolk, UK
Changing incidence and serotype trends in ANCA-associated vasculitis: a 30-year population-based study in Norfolk, UK
Abstract
Objectives
The ANCA associated vasculitides (AAV) are rare diseases with poor outcomes if untreated. Over a 30-y...
Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia
Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia
Abstract
Objective: This study aimed to investigate the inhibitory effect of CTLA4-Ig on anti-AAV neutralizing antibody ...
Interactions of HIV-1 Capsid with Host Factors and Their Implications for Developing Novel Therapeutics
Interactions of HIV-1 Capsid with Host Factors and Their Implications for Developing Novel Therapeutics
The Human Immunodeficiency Virus type 1 (HIV-1) virion contains a conical shell, termed capsid, encasing the viral RNA genome. After cellular entry of the virion, the capsid is rel...

